30
Jul

Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew of Phase III trials in which the drug slashed patients’ bad cholesterol.

…read more

Source: Sanofi, Regeneron prep their PCSK9 cardio contender for FDA review after PhIII sweep

    

0 No comments